Last reviewed · How we verify
Panadol-extra
At a glance
| Generic name | Panadol-extra |
|---|---|
| Sponsor | Damascus University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Upper respiratory tract infection
- Nausea
- Eye pruritus
- Gastritis
- Vomiting
- Pharyngitis streptococcal
- Facial bones fracture
- Laceration
- Blood pressure increased
- Back pain
- Dizziness
- Headache
Key clinical trials
- Musculoskeletal Outcomes Using Tylenol/Ibuprofen vs. Oral Steroids in New Injuries (PHASE4)
- An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain Service (PHASE3)
- Use of Transcutaneous Electrical Nerve Stimulation for Reducing Biologic Injection Site Pain(TENS Study) (NA)
- Hip Arthroscopy Postoperative Opioid Demands (NA)
- OTC Naproxen and Acetaminophen Anti-Inflammatory Action in Dental Implant Patients (PHASE4)
- Management of Post Dural Pucture Headache After Lower Limb Surgeries: Oral Prednisolone vs Oral Pregabalin (NA)
- Pigtail or Chest Tube Placement After Uniportal Video-assisted Thoracoscopic Surgery (NA)
- Postoperative Pain Control in Septum and Sinus Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Panadol-extra CI brief — competitive landscape report
- Panadol-extra updates RSS · CI watch RSS
- Damascus University portfolio CI